Wealth Enhancement Advisory Services LLC Decreases Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Wealth Enhancement Advisory Services LLC cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 39.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,429 shares of the biotechnology company's stock after selling 2,214 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in United Therapeutics were worth $1,057,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Dunhill Financial LLC increased its stake in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares during the last quarter. State of Wyoming purchased a new position in shares of United Therapeutics in the 4th quarter worth approximately $62,000. Curat Global LLC bought a new position in shares of United Therapeutics during the 1st quarter valued at approximately $63,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at approximately $67,000. Finally, Natixis purchased a new stake in United Therapeutics during the 4th quarter valued at $85,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 3,000 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $285.57, for a total transaction of $856,710.00. Following the sale, the director owned 1,750 shares of the company's stock, valued at approximately $499,747.50. This trade represents a 63.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the transaction, the director directly owned 4,883 shares of the company's stock, valued at approximately $1,416,021.17. The trade was a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,681 shares of company stock worth $23,951,939. Insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

Shares of UTHR stock traded up $1.58 during mid-day trading on Thursday, hitting $296.80. The stock had a trading volume of 49,224 shares, compared to its average volume of 444,144. The firm has a market capitalization of $13.39 billion, a P/E ratio of 11.84, a price-to-earnings-growth ratio of 6.37 and a beta of 0.53. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $417.82. The firm's 50-day moving average is $301.18 and its two-hundred day moving average is $323.65.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.17 earnings per share. Analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on UTHR shares. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Bank of America dropped their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Finally, Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $386.15.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.